The Icahn School of Medicine at Mount Sinai (ISMMS) was awarded a $676,000 Project Grant by the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). The grant, titled "EPIGENETIC STUDIES OF CANDIDATE CELLS OF ORIGIN FOR DIFFUSE MIDLINE GLIOMA," is for a research project spanning from September 1, 2024, to August 31, 2026. The funding will support ISMMS's investigation into epigenetic factors that contribute to the development of diffuse...
The Icahn School of Medicine at Mount Sinai will receive $1,521,002 under a three-year Project Grant award from the Defense Health Agency. The grant will support research from August 1, 2023 to July 31, 2026 under the Military Medical Research and Development program (CFDA 12.420). Specifically, the funding will enable research to determine the contribution of lineage intermediate tumor cells during progression to T-SCNC. This work aligns with the Military Medical Research and Development...
The Icahn School of Medicine at Mount Sinai has been awarded a $591,486 Project Grant from the Defense Health Agency under the Military Medical Research and Development program (CFDA 12.420). This 3-year grant, running from September 1, 2023 to August 31, 2026, will support the development of a novel immuno-oncology pipeline for FGFR2 fusion-positive cholangiocarcinoma. The funding will enable the medical school to conduct research aimed at transforming health care for service members and the...
The Icahn School of Medicine at Mount Sinai will receive $760,500 from the Defense Health Agency under a three-year Project Grant award through the Military Medical Research and Development program (CFDA 12.420). The grant will fund research to functionally identify high-dimensional driver combinations in basal-like breast cancer. Through February 1, 2023 to January 31, 2026, this award will support the Icahn School of Medicine's efforts to transform health care for service members and the...
The Icahn School of Medicine at Mount Sinai will receive $422,500 from the Department of the Army Medical Command under a two-year Project Grant award to decipher cell-cell interactions and therapeutic targets in p53-mutant adenocarcinoma at single-cell resolution. The research funded under this award, which runs from September 1, 2022 to August 31, 2024, directly supports the Military Medical Research and Development program administered by the Department of the Army Medical Command. This...
The Icahn School of Medicine at Mount Sinai received a $437,420 Project Grant award from the Department of the Army Medical Command under the Military Medical Research and Development (CFDA 12.420) federal grant program. The grant will support advanced biomedical research initiatives focused on transforming healthcare for military service members and the broader public, with a particular emphasis on investigating innovative approaches to disease prevention, diagnosis, treatment, and management...
The Icahn School of Medicine at Mount Sinai received a $591,694 Project Grant award from the Department of the Army Medical Command on September 15, 2021 to complete work by September 14, 2024. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative solutions for battlefield medicine. Under this award, the Icahn School of Medicine at...
The Defense Health Agency has awarded a $766,079 Project Grant to the Icahn School of Medicine at Mount Sinai to conduct research under the Military Medical Research and Development program (CFDA 12.420). The grant, which runs from September 1, 2023 to August 31, 2026, aims to "UNRAVEL THE EVOLUTION OF MELANOMA WITHIN THE HOST IMMUNE ECOSYSTEM." As a leading private medical research institution, the Icahn School of Medicine at Mount Sinai has a history of providing a wide range of...
The Department of the Army Medical Command, through the Military Medical Research and Development federal grant program (CFDA 12.420), has awarded a $2,028,000.00 Project Grant to the Icahn School of Medicine at Mount Sinai (ISMMS) in New York, NY. The grant, awarded on April 1, 2025, will support the identification of epigenetically driven vulnerabilities in metastatic castration-resistant prostate cancer. ISMMS, a prominent academic medical center and federal contractor, will leverage its...
The Icahn School of Medicine at Mount Sinai will target the shedding of transmembrane PD-L1 to enhance therapeutic efficacy of immune checkpoint inhibitors under a $169,499 Project Grant from the Department of the Army Medical Command. The grant is part of the Military Medical Research and Development program (CFDA 12.420), which supports basic, applied, and advanced biomedical research to transform military and public health care through innovative and impactful investigations. Specifically,...